Cemiplimab

• Cemiplimab is an immunotherapy drug that targets the PD-1 protein on T-cells, helping the immune system fight cancer.
• It is primarily used to treat specific types of advanced skin cancers, such as cutaneous squamous cell carcinoma and basal cell carcinoma, and certain non-small cell lung cancers.
• The drug works by blocking the PD-1 pathway, which helps the immune system recognize and attack cancer cells.
• Common side effects can include fatigue, musculoskeletal pain, rash, and diarrhea, with more serious immune-related adverse events possible.
• Treatment with Cemiplimab requires careful monitoring by healthcare professionals to manage efficacy and side effects.

What is Cemiplimab and How It Works

Cemiplimab is a monoclonal antibody that functions as an immune checkpoint inhibitor. Specifically, it targets the programmed cell death protein 1 (PD-1) receptor found on T-cells, which are crucial components of the immune system. By binding to PD-1, Cemiplimab prevents cancer cells from deactivating these T-cells, thereby allowing the immune system to more effectively identify and destroy malignant cells. This mechanism represents a significant advancement in oncology, leveraging the body’s natural defenses against cancer.

The way Cemiplimab works involves disrupting a critical pathway that many cancer cells exploit to evade immune surveillance. Normally, the interaction between PD-1 on T-cells and PD-L1 (Programmed Death-Ligand 1) on cancer cells acts as an “off switch” for the T-cell, preventing it from attacking the tumor. By blocking PD-1, Cemiplimab essentially removes this brake, reactivating the T-cells and enhancing their ability to mount an anti-tumor response. This targeted approach helps restore the immune system’s natural capacity to fight cancer.

Cemiplimab Uses and Treatment Details

Cemiplimab is approved for the treatment of various advanced cancers. It is primarily used for certain patients with cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and non-small cell lung cancer (NSCLC). For CSCC, it is indicated for patients with metastatic or locally advanced disease who are not candidates for curative surgery or radiation. In BCC, it is used for patients with locally advanced or metastatic disease who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. For NSCLC, it is indicated as a first-line treatment for patients with advanced NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%) with no EGFR, ALK, or ROS1 aberrations.

Cemiplimab treatment information typically involves intravenous infusion administered by a healthcare professional. The dosage and frequency depend on the specific cancer type and the patient’s overall health, but it is commonly given every two or three weeks. Before initiating treatment, patients undergo thorough evaluations, including biomarker testing (such as PD-L1 expression for NSCLC), to determine their eligibility and potential responsiveness to the therapy. Ongoing monitoring throughout the treatment course is essential to assess efficacy and manage any emerging side effects.

• Metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC)
• Locally advanced or metastatic basal cell carcinoma (BCC)
• First-line treatment for advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression

Potential Cemiplimab Side Effects

Like all medications, Cemiplimab can cause side effects, which result from its immune-modulating activity. These are often referred to as immune-related adverse events (irAEs) because they occur when the activated immune system mistakenly attacks healthy tissues. The severity and type of Cemiplimab side effects can vary significantly among individuals.

Common side effects often include fatigue, musculoskeletal pain, rash or itching, diarrhea, nausea, and decreased appetite. More serious, though less common, immune-related adverse events can affect various organ systems and may require immediate medical attention. These can include inflammation of the lungs (pneumonitis), colon (colitis), liver (hepatitis), endocrine glands (thyroid, adrenal, pituitary), and kidneys (nephritis). Patients are closely monitored for these potential complications, and prompt intervention, often involving corticosteroids, is crucial for managing severe irAEs. Patients should report any new or worsening symptoms to their healthcare team immediately.